Shares of pharmaceutical giant Amgen (AMGN) are attempting to bounce back after suffering a steep drop of 7.1% yesterday.

As an aside, in the tech space, see What’s Happening With Snap Stock? Although the recent Amgen update didn’t bode well with ...

Fintel reports that on November 14, 2024, Citigroup initiated coverage of Amgen (NasdaqGS:AMGN) with a Neutral recommendation ...

Shares of Amgen (AMGN) added more than 3% in pre-market trading, rebounding from a 7.1% retreat in the previous ...

Amgen (AMGN) announced the presentation of new data across its rare disease portfolio and pipeline at the annual American College of ...

Amgen (AMGN) stock spiked after the company ruled out out bone density concerns linked to obesity drug MariTide, following a ...

In a report released today, Umer Raffat from Evercore ISI maintained a Buy rating on Amgen (AMGN – Research Report). The company’s ...

Amgen addresses safety concerns for its weight loss drug MariTide after new data suggests a potential 4% reduction in bone ...

On Thursday, Amgen Inc (AMGN) stock saw a modest uptick, ending the day at $321.91 which represents a slight increase of $0.12 or 0.04% from the prior close of $321.79. The stock opened at $322 and ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Analysts have set 12-month price targets for Amgen, revealing an average target of $349.0, a high estimate of $405.00, and a ...

Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone mineral density, a ...